In this issue:
Steroid-sparing therapy and perianal fistulising complication risk in CD
Outcomes better with ustekinumab than vedolizumab in CD with prior anti-TNF failure
Ustekinumab dose escalation in CD after insufficient response to standard therapy
Transperineal ultrasound predicts UC endoscopic and histological healing
Dual biologic therapy in refractory CD
Frailty increases infection risk after immunosuppression for IBD
PSC-IBD in children
Risk of more advanced lesions in IBD with dysplasia
Adding azathioprine to anti-TNF switch in relapsed IBD
COVID-19 outcomes in IBD patients
Please login below to download this issue (PDF)